Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis

Hepatology

Volumn 60, Issue 5, 2014, Pages 1659-1673

  Song, Ruipeng ^a   Song, Huiwen ^b   Liang, Yingjian ^a   Yin, Dalong ^a   Zhang, Heng ^c   Zheng, Tongsen ^a   Wang, Jiabei ^a   Lu, Zhaoyang ^a   Song, Xuan ^a   Pei, Tiemin ^a   Qin, Youyou ^a   Li, Yuejin ^a   Xie, Changming ^a   Sun, Boshi ^a   Shi, Huawen ^a   Li, Shuai ^a   Meng, Xianzhi ^a   Yang, Guangchao ^a   Pan, Shangha ^a   Zhu, Jiyuan ^a   Qi, Shuyi ^a   Jiang, Hongchi ^a   Zhang, Zhiyong ^d   Liu, Lianxin ^a,e   more..

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CHINA THREE GORGES UNIVERSITY   (China)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ADENOSINE TRIPHOSPHATASE INHIBITORY FACTOR 1; BETA CATENIN; CIAP2 PROTEIN; CYTOMEGALOVIRUS ANTIGEN PP65; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VIMENTIN; ATPASE INHIBITORY PROTEIN; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ALGORITHM; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL MIGRATION; CELL MOTILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CHINA; COHORT ANALYSIS; EPIDEMIOLOGY; FEMALE; LIVER TUMOR; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROGNOSIS; SECONDARY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CHINA; COHORT STUDIES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHOSPHOPROTEINS; PROGNOSIS; PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL MATRIX PROTEINS;

EID: 84922227575     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27312     Document Type: Article

References (24)

1. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010;14:249-258.
2. Oyagbemi A, Azeez O, Saba A. Hepatocellular carcinoma and the underlying mechanisms. African Health Sci 2010;10:93.
3. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012;40:1733.
4. Chen EI. Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr 2012;44:619-622.
5. Faccenda D, Tan C, Seraphim A, Duchen M, Campanella M. IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death Differ 2013;20:686-697.
6. Filomeni G, Bolaños JP, Mastroberardino PG. Redox status and bioenergetics liaison in cancer and neurodegeneration. Int J Cell Biol 2012;2012.
7. Formentini L, Sánchez-Aragó M, Sánchez-Cenizo L, Cuezva JM. The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. Mol Cell 2012;45:731-742.
8. Theiss AL. Sphingosine-1-phosphate: driver of NFκB and STAT3 persistent activation in chronic intestinal inflammation and colitis-associated cancer. JAK-STAT 2013;2:0-1.
9. Razani B, Reichardt AD, Cheng G. Non-canonical NF-κB signaling activation and regulation: principles and perspectives. Immunol Rev 2011;244:44-54.
10. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng P-H, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat Immunol 2008;9:1364-1370.
11. Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene 2011;31:3607-3620.
12. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An autocrine loop between TGF-β1 and the transcription factor Brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther 2013;12:1805-1815.
13. Kaur J, Sawhney M, DattaGupta S, Shukla NK, Srivastava A, Walfish PG, et al. Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression. PLoS One 2013;8:e67361.
14. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-1891.
15. Parker LH, Schmidt M, Jin S-W, Gray AM, Beis D, Pham T, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 2004;428:754-758.
16. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh B-C, Lidov HG, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004;119:285-298.
17. Domenis R, Comelli M, Bisetto E, Mavelli I. Mitochondrial bioenergetic profile and responses to metabolic inhibition in human hepatocarcinoma cell lines with distinct differentiation characteristics. J Bioenerg Biomembr 2011;43:493-505.
18. Sánchez-Aragó M, Formentini L, García-Bermúdez J, Cuezva JM. IF1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. Cell Cycle 2012;11:2963-2964.
19. Katoh M, Katoh M. Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1α, POU/OCT, and NF-κB. Int J Oncol 2009;34:1737.
20. Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T. Suppression of metastasis by nuclear factor kB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Scie 2004;95:18-24.
21. Terasaki H, Kase S, Shirasawa M, Otsuka H, Hisatomi T, Sonoda S, et al. TNF-α decreases VEGF secretion in highly polarized RPE cells but increases it in non-polarized RPE cells related to crosstalk between JNK and NF-κB pathways. PLoS One 2013;8:e69994.
22. Kumar M, Allison DF, Baranova NN, Wamsley JJ, Katz AJ, Bekiranov S, et al. NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. PLoS One 2013;8:e68597.
23. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-665.
24. Sánchez-Aragó M, Formentini L, Martínez-Reyes I, García-Bermudez J, Santacatterina F, Sánchez-Cenizo L, et al. Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers. Oncogenesis 2013;2:e46.